EU approves first biosimilar monoclonal antibody
This article was originally published in SRA
Executive Summary
Celltrion/Hospira's own version of J&J/Merck & Co's Remicade, Inflectra (infliximab) has become the first biosimilar monoclonal antibody to win approval in the EU after the European Commission gave the drug the formal green light1. The approval marks a new era for biosimilars in Europe.